This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.
By integrating a real-time frailty risk score into the electronic medical record (EMR), presenting stroke severity and other variables, we can proactively identify who will benefit from immediate surgery and who may need pre-habilitating before surgery to achieve better outcomes.
This launch coincides with the receipt of pass-through status by the CMS, effectiveApril 1, securing a drug-specific Healthcare Common Procedure Coding System (HCPCS) billing code and coverage for traditional Medicare beneficiaries.
Autologous CD34 cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials, European Heart Journal, 2018.
BackgroundHuman pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) show tremendous promise for cardiac regeneration following myocardial infarction (MI), but their transplantation gives rise to transient ventricular tachycardia (VT) in large-animal MI models, representing a major hurdle to translation.
Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.
This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment. a huge win: CMS significantly increases Medicare payments for cardiac CT. For more information on Revolution Vibe, please visit gehealthcare.com. 2012) 380:2095128.
The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.
To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. Stroke recovery is a challenging process that extends for months after hospital discharge. This missing puzzle piece matters now more than ever.
a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company's IDE pivotal trial. These patients have very poor outcomes in terms of death and rehospitalization and therefore new therapy options are critically needed," stated Dr. Chehab.
Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. In recent years, numerous health care challenges have been tackled, some making headlines, while others quietly escalate under the radar – like polypharmacy.
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.
Introduction:There are significant and longstanding inequities in stroke prevalence and care as well as outcomes. Social determinants of health (SDOH) are known to be a risk factor in post-stroke recovery. SDOH also put individuals at higher risk for 90-day mortality. 12.5%, and 90-day readmissions ranging from 18.9%
Introduction:There are significant and longstanding inequities in stroke prevalence and care as well as outcomes. Social determinants of health (SDOH) are known to be a risk factor in post-stroke recovery. SDOH also put individuals at higher risk for 90-day mortality. 12.5%, and 90-day readmissions ranging from 18.9%
Clinical data extracted from an EMR-driven registry were linked to PAC utilization information retrieved from a CMS Qualified Entity with 80% data for the Texas state population (including 100% of Medicare Fee-for-Service). Factors associated with 1-YR outcomes were evaluated via multivariate logistic regression. female; 63.6%
Practices with Ambulatory Surgery Centers (ASCs) are becoming particularly attractive, as CMS added 23 ASC cardiac catheterization and PCI codes in just the last two years. Previous studies have shown that PE ownership hurts care quality and outcomes.
Methods:Data were retrieved from a CMS Qualified Entity housing healthcare utilization data for ≥80% of the Texas state population (100% of Medicare Fee-for-Service). Conclusion:Post stroke transitions of care patterns may yield insights as to the long-term trajectory of outcomes. and 82.3% (Panel D).Conclusion:Post
The Alzheimers Associations expert guidance is to avoid co-prescribing; however, CMS and FDA do not restrict or warn against it. Monthly model outcomes included ICH, ischemic stroke, cognitive impairment, quality-adjusted life months (QALMs), and survival. The model was populated with the Health and Retirement Study-AF cohort.
Conclusion:Cluster analyses can elucidate high-risk patient profiles and guide in identifying intervenable targets and prioritizing provision of appropriate care, including rehabilitation, to optimize long-term patient outcomes. Post acute care at an inpatient rehabilitation facility minimized the risk of low HT (vs. vs. 28.5%) (Fig.
In late 2023, CMS released the 2024 Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). Report 6 measures, including one Outcome or other High Priority measure for 12 months on at least 70% of eligible encounters to receive a score based on 2023 National Benchmarks.
Removing these barriers would allow surgeons, physicians, hospitals, health systems, and others to conduct longitudinal analyses and gain new insights into long-term outcomes for patients undergoing procedures such as coronary artery bypass grafting (CABG)—the most common operation performed by cardiac surgeons.
These features are pivotal in ensuring accurate diagnoses, streamlined workflows, and improved patient outcomes. Regulation-Ready with AUC Integration GEMMS One simplifies compliance by seamlessly incorporating the Complex Appropriate Use Criteria (AUC) mandated by CMS.
Key features include: Compliance Under Appropriate Use Criteria (AUC) – GEMMS ONE meets CMS standards and requirements by including an AUC orders module, part of its integrated system. This enables early intervention, minimizes hospital admissions, and helps improve patient outcomes.
The epidemiology of AIS and concomitant CM subtypes is not well-described.Methods:Adult hospitalizations in the National Inpatient Sample (NIS) from 2018-2020 with diagnosis of AIS and concomitant CM were characterized by CM etiologies using International Classification of Diseases-10 codes.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. Available at: [link].
Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial. Secemsky, M.D.,
Without this information, it’s nearly impossible for patients to make informed choices about managing their condition, leading to poor long-term outcomes. As insurance coverage improves , especially through programs like CMS, more patients can access this life-changing technology.
They matter because their member bases are growing fast, and they’re driving both better outcomes and lower costs. And their newest program, called ACO Reach, has attracted hundreds of applicants, as CMS seeks to ensure historically underserved patients are fully included.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content